Arcus Biosciences, Inc.
RCUS
Rank in Stocks
#4987
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops... Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The companyโs development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Share Price
$18.95
Last synced: 2026-11-09
Market Cap
$2.68B
Change (1 day)
3.67%
Change (1 year)
-6.60%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Arcus Biosciences, Inc. (RCUS)
Category
Healthcare
EPS for Arcus Biosciences, Inc. (RCUS)
EPS as of September 2026 TTM: $-3.66
According to Arcus Biosciences, Inc.'s latest financial reports, its current EPS (TTM) is $-3.66. At the end of 2025 the company had an EPS of $-3.29, a decrease compared to its 2024 EPS of $-3.14.
EPS history for Arcus Biosciences, Inc. from 2016 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.66 | 11.25% |
| 2025 | $-3.29 | 4.78% |
| 2024 | $-3.14 | -24.34% |
| 2023 | $-4.15 | 11.86% |
| 2022 | $-3.71 | -588.16% |
| 2021 | $0.76 | -133.93% |
| 2020 | $-2.24 | 16.06% |
| 2019 | $-1.93 | 34.97% |
| 2018 | $-1.43 | -33.80% |
| 2017 | $-2.16 | 195.89% |
| 2016 | $-0.73 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -527.87% |
US
|
|
| $-7.07 | 93.17% |
US
|
|
| $-5.29 | 44.54% |
AU
|
|
| $12.88 | -451.92% |
BE
|
|
| $21.56 | -689.07% |
NL
|
Questions about Arcus Biosciences, Inc.'s earnings per share (EPS)
What is Arcus Biosciences, Inc.'s earnings per share (EPS)?
Arcus Biosciences, Inc.'s earnings per share (EPS) over the last twelve months is $-3.66, as of Sep 2026.
What was Arcus Biosciences, Inc.'s earnings per share (EPS) in 2025?
In 2025, Arcus Biosciences, Inc.'s earnings per share (EPS) was $-3.29, compared with $-3.14 in 2024.
How has Arcus Biosciences, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Arcus Biosciences, Inc.'s earnings per share (EPS) was highest in 2021 ($0.76) and lowest in 2023 ($-4.15).
How does Arcus Biosciences, Inc.'s earnings per share (EPS) compare with similar companies?
Arcus Biosciences, Inc.'s earnings per share (EPS) ($-3.66) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.